In short
Calcium hydrogen phosphate dihydrate is a calcium- and phosphorus-containing mineral substance. In the clinical trial listed here, it is not the medicine being tested but the placebo, the inactive comparison substance. The trial investigates acetylsalicylic acid (aspirin) against placebo in children with thrombotic episodes in superficial venous malformations, with 34 participants in a Phase 3 design.
Key points
- Calcium hydrogen phosphate dihydrate is a mineral substance containing calcium and phosphorus.
- It is used in this trial as the placebo, not as the active treatment.
- The trial is a Phase 3 study with 34 children aged 6 to 17 years.
- The condition studied is thrombotic episodes in superficial venous malformations.
- The trial compares aspirin plus a local NSAID with placebo plus a local NSAID.
- The main measure is pain relief over 3 to 14 days of treatment.
What is calcium hydrogen phosphate dihydrate?
Calcium hydrogen phosphate dihydrate is a mineral substance that contains calcium and phosphorus. It is also known as dibasic calcium phosphate dihydrate, dicalcium phosphate dihydrate, or calcium monohydrogen phosphate dihydrate. The Canadian regulator classifies it as a mineral under the Natural Health Products Regulations. In the clinical trial listed on this page, it appears in the product record as the placebo arm, meaning it serves as the inactive comparison substance rather than as a medicine being tested.
How does calcium hydrogen phosphate dihydrate work?
As a mineral, calcium hydrogen phosphate dihydrate supplies calcium and phosphorus. It has no active drug effect in the trial considered here; it is used as a placebo, an inactive substance that looks like the treatment being tested but contains no active medicine. In natural health products it is also used for non-medicinal purposes, such as a binder, diluent, or thickening agent.
Which conditions is it used or studied for?
- Thrombotic episodes in superficial venous malformations in children — this is the condition studied in the trial, where calcium hydrogen phosphate dihydrate is used as the placebo comparator.
How is calcium hydrogen phosphate dihydrate given?
In this trial, calcium hydrogen phosphate dihydrate is given by mouth, in an oral form. The trial record lists a total amount of 1920 mg for the oral route. The substance is a chemically synthesised mineral.
What do the clinical trials show?
One clinical trial is recorded for this substance, and in it calcium hydrogen phosphate dihydrate is the placebo, not the treatment under investigation. The trial is a Phase 3, randomised, double-blind, cross-over, multicentre study in children aged 6 to 17 years with thrombotic episodes in superficial venous malformations. It aims to enrol 34 participants.
The trial compares acetylsalicylic acid (aspirin) given by mouth plus a local non-steroidal anti-inflammatory drug (diclofenac gel) against placebo plus the same local NSAID. The main measure is the effect on pain over a treatment period of 3 to 14 days. The trial status is authorised, meaning it has received approval to proceed.
What side effects are known?
The available source does not list side effects for calcium hydrogen phosphate dihydrate. It does note a maximum tolerable intake of up to 70 mg per kilogram of body weight daily for phosphorus from all sources.